GARD is a pan-cancer predictor of clinical outcome in radiation treated patients.

Jacob G. Scott[1,2,3,4,†,*], Geoffrey Sedor[4,†], Patrick Ellsworth[4], Jessica A. Scarborough[1,3,4], Kamran Ahmed[5], Steven A. Eschrich[6], Javier F. Torres-Roca[5,*], and Michael W. Kattan[7,*]

[1]Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
[2]Radiation Oncology Department, Cleveland Clinic, Cleveland, OH
[3]Systems Biology and Bioinformatics, School of Medicine, Case Western Reserve University, Cleveland, OH
[4]School of Medicine, Case Western Reserve University, Cleveland, OH
[5]Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL
[6]Department of Biostatistics and Biomedical Informatics, Moffitt Cancer Center, Tampa, FL
[7]Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
[*]scottj10@ccf.org, javier.torresroca@moffitt.org, kattanm@ccf.org
[†]contributed equally

ABSTRACT

Purpose/Objectives: Despite advances in cancer genomics, radiation therapy (RT) is still prescribed based on an empiric one-size-fits-all paradigm. Previously, we proposed a novel algorithm using the genomic adjusted radiation dose (GARD) to personalize RT prescription dose based on the *biological effect* of a given physical RT dose, calculated using individual tumor genomics – hypothesizing that the extra genomic dimension would reveal differences in clinical outcome not apparent with standard physical RT dose alone. To test this hypothesis, and the GARD-based RT dosing paradigm, we performed a pooled pan-cancer analysis in 9 separate clinical cohorts of 1,574 unique patients that represent all available cohorts with the data required to calculate GARD, together with clinical outcome.

Materials/Methods: We collected 9 previously-published datasets for which all information to calculate GARD was available. Two clinical endpoints were defined: (i) time to first recurrence and (ii) overall survival. The recurrence and survival analysis included a total of 1,257 (972 +RT, 285 -RT) and 636 patients (414 +RT, 222 -RT), respectively. A stratified Cox proportional hazard regression analysis model was constructed for each disease site and each outcome using GARD as the covariate, and a common GARD effect was estimated. Secondary Cox models were constructed similarly using total RT dose and sham-GARD (for -RT patients) as the covariates for comparison. Restricted cubic splines with 3-5 knots were included to allow for possible nonlinear associations. Interaction tests between GARD and whether patients received RT were performed using the Wald statistic for all cohorts.

Results: Pooled analysis of all available data reveal that GARD is a continuous predictor of recurrence (HR = 0.984, CI [0.982, 0.996], p= 0.004) and survival (HR = 0.975, CI [0.958, 0.993], p= 0.005) in RT treated patients. There was no significant relationship between physical RT dose or sham-GARD and survival or recurrence in any group, or in the pooled analysis. The interaction test revealed the effect of GARD on survival depends on whether or not that patient received RT (Wald statistic: p=0.026), as is the effect of GARD on first recurrence for all but those patients treated to the lowest GARD (for patients with GARD > 19.2Gy, Wald statistic: p=0.04).

Conclusions: Biologic effect, as quantified by GARD, is significantly associated with recurrence and survival in a continuous manner in RT treated patients, and physical RT dose is not. We propose that genomics should be integrated into radiation dosing decisions, using a GARD-based framework as the new paradigm for personalizing RT treatment.

Key Words: radiation therapy, genomics, mathematical model, personalized medicine

Introduction

Radiation therapy (RT) is the oldest and single most utilized cytotoxic therapy in oncology and is responsible for 40% of all cancer cures. There have been innumerable technological advances over RT's > 100 year history, allowing for better *anatomic RT dose targeting*. There have not, however, been such advances in the *physical RT dosing paradigm*, where we still prescribe one-size-fits-all uniform doses to patients using a protracted-fractional method, based on experiments first done on rams and rabbits more than 80 years ago.[1] Physical RT dose is prescribed based on energy absorbed by tissue (measured in Gray) and historically the field has recognized that the physical interaction of radiation with tissue results in a *biological effect* (e.g. DNA damage, clinical tumor response, carcinogenesis).[2] However, there is significant heterogeneity in the biological effect of a given physical RT dose between cancer types – *patients we treat uniformly do not have a uniform response*. We have shown previously that this difference in radiation induced biological effect can be quantified at the patient level using tumor genomics, and subsequently, that it can therefore be modulated by the treating radiation oncologist.[3,4] While the sequencing of the human genome changed the therapeutic paradigm in medical oncology, the same is not yet true for radiation oncology, where an empiric paradigm is still utilized to prescribe one-size-fits-all RT dosing: that is, all patients with a given cancer type receive the same prescription RT physical dose.

The clinical heterogeneity of radiation response, even within disease groups, is well established. Further, that this heterogeneity is at least partly driven and influenced by changes in the tumor genome is now accepted – indeed, large-scale classification efforts have been performed to understand these differences.[5–7] There have also been several efforts to understand surrogate genomic metrics for individual patient's resistance to radiation,[8] as well as imaging-based studies.[9] None of these efforts, however, considers the explicit relationship between intrinsic tumor genomics and physical RT dose – the standard, and fundamental, parameter in radiation therapy.

We previously introduced the gene expression-based radiosensitivity index (RSI), a biomarker of tumor radiosensitivity, which we, and others, have validated in multiple cohorts spanning various disease sites by dichotomizing patients as either radiosensitive or radioresistant.[3,4,10–22]Subsequently, we developed the Genomic Adjusted Radiation Dose (GARD), which integrates RSI and physical RT dose to *quantify the biological effect of a given physical RT dose* in an individual patient.[2,4] This created the first opportunity to understand the relationship between intrinsic tumor radiation sensitivity and the biological effect of a given RT dose. Further, GARD allows a clinician to dose a patient's tumor to a desired biological effect, permitting personalization of physical RT dose: a new RT prescription paradigm in which information about physical RT dosing is enriched by a genomic dimension.

To validate the GARD-based RT dosing paradigm, we performed a pooled, pan-cancer analysis to compare disparate outcomes and disease sites in which we utilize all available clinical datasets with enough information to calculate GARD.[23]. In this manuscript, we analyze the predictive ability of biologic effect, quantified by GARD, for recurrence and survival across 6 disease sites, encompassed by 9 separate cohorts, totaling 1,574 patients.

Material and Methods

Clinical Cohorts and Endpoints

We collected a series of 9 previously-published datasets for which we had all information to calculate GARD (gene expression via Affymetrix microarray, physical RT dose and dose per fraction) and clinical outcome. GARD was calculated as previously reported, scaling RSI within each cohort.[4] These cohorts, summarized in **Table 1**, include patients treated with RT for breast cancer (BC), including triple negative breast cancer (TNBC)[15,16,24], glioma[11], pancreatic[17], endometrial (EC)[21], head and neck[10] (HNC) and non-small cell lung[4] cancers (NSCLC). In addition, it includes patients that were not treated with RT as a negative control, and to determine the predictive efficacy of GARD. While the range of physical RT dose was limited in these modern cohorts to values near standard of care, but adding the genomic dimension and calculating GARD reveals a wide range of predicted biologic effect (see **Supplemental Figures 1 and 2**).

We define two clinical endpoints: time to first recurrence and overall survival. Time to first recurrence included time to local, loco-regional and distant metastasis. Combining all clinical cohorts, we report the results of two independent analyses of the recurrence and survival endpoints separately. Basic descriptive outcome measures for the clinical cohorts can be seen in **Supplemental Tables 1 and 2**, and Kaplain-Meier survival plots for each cohort in **Supplemental Figures 3 and 4**. Individual disease sites were analyzed with Cox proportional hazards models. The pooled analysis was analyzed with a stratified Cox proportional hazards model, and a χ-squared statistic calculated using the Wald test. Interaction between GARD and whether patients received radiation therapy was calculated for both patient pools using the Wald statistic. Restricted cubic splines with 3-5 knots were included to allow for possible nonlinear associations.

Table 1. Cohorts included in the recurrence and survival pooled analysis. All available cohorts which had RSI, physical radiation dose and clinical (recurrence and/or survival) outcomes information were included in the analysis. *n.b. A total of 20 patients were censored from the TCGA Glioma cohort who were prescribed short course, palliative radiation doses.

Disease site	No. of patients	No. of events	Description and reference
		Recurrence Cohorts	
Breast	788	242	adjuvant RT for BC[15,16]
TNBC	113	29	adjuvant RT for TNBC[24]
Endometrium	204	18	adjuvant RT for EC[21]
Head and Neck	92	28	concurrent chemoradiation for HNC[3]
NSCLC	60	23	adjuvant RT for NSCLC[4]
Total	1257	340	
		Survival Cohorts	
TNBC	55	9	adjuvant RT for TNBC[24]
Endometrium	204	62	adjuvant RT for EC[21]
Glioma*	244	190	concurrent chemoradiation (temozolomide) for glioma[11]
NSCLC	60	38	adjuvant RT for NSCLC[4]
Pancreas	73	50	adjuvant RT for pancreas[17]
Total	636	349	

Pooled Analysis Method

In order to statistically compare cohorts which are heterogeneous in outcome and disease type, we used a Cox proportional hazards modelling, stratified by disease site, with GARD as the only covariate. This allowed each disease site to have a different baseline hazard function, yet still determine a common GARD effect. Separate Cox models for each disease site were also constructed for those patients who did not receive RT. To calculate GARD for patients that did not receive RT (sham GARD), we assumed that they all received standard of care dose sham RT (50 Gy in 25 fractions for breast, 50 Gy in 25 fractions for pancreas, 60 Gy in 30 fractions for glioma, 54 Gy in 27 fractions for endometrium). We also utilized restricted cubic splines, with 3-5 knots, in order to allow for non-linear effects.

Results

GARD is a pan-cancer predictor of clinical outcome in RT-treated patients

To determine the association between GARD and clinical outcome in RT-treated patients, we performed Cox regression analysis for each disease cohort. The results of this analysis (see **Figure 1, top**), in are represented as a forest plot demonstrating the impact of GARD on any recurrence and survival endpoints in each of the individual cohorts studied (see **Supplemental Figure 3** for this information in tabular form.) As a negative control, we performed the same analyses in patients treated without RT (GARD calculated using standard of care dose sham radiation) which showed no association between GARD and either any recurrence or overall survival (see **Figure 1, middle** and **Supplemental Figure 5**). Pooled analysis of all available data reveal that GARD is a continuous predictor of recurrence (HR = 0.984, CI [0.982, 0.996], p= 0.004) and survival (HR = 0.975, CI [0.958, 0.993], p= 0.005).

To determine whether GARD is a pan-cancer predictor of clinical outcome in RT-treated patients, we performed an interaction test between GARD and treatment (with RT or without RT) for both outcome types. In the simplest, linear model, the interaction test for survival revealed a significant interaction between GARD and RT treatment status (Wald statistic, p= 0.026, see **Supplemental Table 6**), but not for recurrence (Wald statistic, $p = 0.816$, see **Supplemental Table 7**). However, further analysis using a non-linear restricted cubic splines reveals for GARD values > 19.2Gy, the interaction test for recurrence reaches significance (Wald statistic, p= 0.04, (see **Supplemental Table 8**). This disparity is likely secondary to the inability to quantify the added benefit of RT for those patients with minimal biologic treatment impact (radioresistant patients receiving low RT doses - in another words, low GARD). It is noteworthy that even in these regions of extremely low effect, a linear model still predicts benefits to OS for GARD.



Figure 1. Individual Cox proportional hazard ratios for each disease site and outcome. We present three separate Cox proportional hazards models. **Top:** We use GARD as a covariate for OS and first recurrence for each site individually, and for the composite. In the composite, GARD is significantly associated with both OS ($p = 0.005$ and recurrence ($p = 0.004$). **Middle:** We use sham-GARD as the covariate for the same analysis. These are patients not treated with RT, but we calculated GARD using what would have been standard of care. There are no significant associations. **Bottom:** We use physical RT dose as the covariate for the same analysis; no sites or groups are significantly associated. Recurrence (solid) and survival (dotted) were used as the outcome of interest for all disease sites. Each point represents the hazard ratio per unit GARD with horizontal lines showing 95% CI, which are symmetric (n.b. CIs for Endometrium and Pancreas are truncated on the right in the physical RT dose cohort for ease of visual analysis). In both subplots, values to the left of the intercept, $HR = 1$, favor a predictive correlation with outcome of interest.

RT dose does not predict outcome until modulated by genomics (GARD)

Historically, the RT dosing prescription paradigm has been guided by physical RT dose. We have previously shown that the effect of a given RT dose, as quantified by GARD, varies widely between patients, and is associated with changes in clinical outcome.[4] To test how GARD compares directly to physical RT dose, we performed a second Cox regression analysis for each cohort using physical RT dose as the covariate. We found no association between physical RT dose and survival ($p = 0.889$) or recurrence ($p = 0.941$) (**Figure 1, bottom**); in contrast to GARD, which predicted both survival ($p = 0.005$) and recurrence ($p = 0.004$) in the pooled analysis (see **Supplemental Figure 4** for Cox model results in tabular form for physical RT dose).

Increasing GARD results in a statistically significant decrease in relative hazard for survival and recurrence

Having shown that GARD is predictive of outcome in radiation treated patients, and is superior to physical RT dose, we sought to understand the effect of increasing GARD for any patient. We subsequently fit a relative hazard function stratified by disease

site/cohort to assess whether GARD has an association with the outcome of interest (recurrence and survival). The resulting regression found GARD to be a statistically significant, linear variable for both outcome types analyzed, with an increase in GARD corresponding to a decrease in the GARD-specific relative hazard (first recurrence: χ-squared $= 8.3$, $p = 0.004$; overall survival: χ-squared $= 7.9$, $p = 0.005$, see **Supplemental Figure 7**). In order to further convey the clinical significance of these results, disease site and baseline hazard functions were reintroduced in order to predict absolute survival probabilities at 3 years, plotted as a nomogram beneath each outcome model (see **Figure 2**).



Figure 2. GARD is a statistically significant, continuous predictive biomarker of survival and recurrence in RT treated patients. We plot the relative hazard per unit GARD at 3-years as predicted by the stratified Cox model for both **(A)** overall survival and **(B)** first recurrence. The impact of the relative hazard as determined by GARD can be interpreted in the context of a specific site, as shown in nomogram form below the waterfall, where predicted absolute survival probability underlies the corresponding GARD value for each cohort.

Discussion

Radiation therapy is the single most commonly utilized anti-cancer therapy and is currently prescribed based on an empiric, one-size-fits-all dosing paradigm. In this analysis we have shown that biological effect, as quantified by GARD, is a statistically significant pan-cancer predictor of recurrence and survival in RT treated patients. Critically, we demonstrate that the interaction of GARD and RT is significant for overall survival, establishing GARD as predictive of RT-treatment benefit. We utilized all available clinical data, totalling 1,574 patients, spanning 6 disease sites. A paradigm driven by GARD defines an actionable measure of biological effect of RT in a given patient. This permits a reframing of our thinking, enabling us to modulate and personalize the biological effect of radiotherapy we deliver to our patients, and establishes the first clinically-validated approach to genomic-based radiation oncology.

Here we demonstrate that the biologic effect induced by physical RT dose, as quantified by GARD, is associated with both survival and outcome, while the physical RT dose is not. This makes sense in the setting of recent clinical trials of RT dose escalation in unselected patients, which have not been shown to improve overall survival. This does not mean that physical RT dose is not an important parameter. Because the biological effect of a given dose varies widely for individual patients, small changes near the ranges now accepted as standard of care are not uniform, so the effects can be obfuscated in unselected patients. This suggests that to make further progress, like in medical

oncology, we need to incorporate the extra dimension of genomics to provide a higher resolution understanding of our patients and to affect their outcomes. Thus, it is critical to shift the radiotherapy dosing paradigm from one that is based on physical RT dose to one that is based on biological effect, as quantified by GARD.

The fundamental goal of radiation treatment planning is to deliver maximal physical RT dose to the tumor while minimizing dose to normal tissue. The integration of 3D anatomy into radiation treatment planning systems, brought about by the invention of the CT scanner, enabled the geometric optimization of radiation fields. This led to a shift from one-size-fits-all radiotherapy field shapes to ones that are anatomically personalized, improving the ability of radiation oncologists to further spare normal tissue for each individual patient. The resultant techniques (e.g. Intensity Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT)) have been shown to decrease toxicity in Phase 3 clinical trials and change standard of care in several cancers including lung and prostate. In other words, the development of radiation planning optmization techniques led to significant clinical gains for RT-treated patients. Similarly, we propose that GARD can be utilized to maximize the biological effect of physical dose to the tumor, while respecting standard of care guidelines for normal tissue. This change would enable the field to move away from the empiric one-size-fits-all RT dose paradigm to one where dose is based on genomics and personalized. In a recent study, we demonstrated that GARD-optimization of tumor physical dose, can be achieved within standard of care guidelines for up to 75% of non-small cell lung cancer patients treated with post-operative RT.[25] We do not suggest abandoning physical RT dose, but instead, as with the CT scanner, we suggest enhancing dose with another dimension, genomic data, allowing us to see individual patient's radiation response at a higher resolution.

Recently, multiple phase 3 randomized clinical trials failed to demonstrate improvements in clinical outcome after uniform dose escalation. How do you reconcile the results of these trials with the proposal that each unit increase in GARD positively impacts clinical outcome? While this stands in contrast to the recent negative trials of dose-escalation, it is not dissonant. First, given our new understanding of heterogeneous response to homogeneous physical RT dose, we realize that uniform dose escalation without understanding intrinsic radiosensitivity is actually not uniform. A GARD-based approach allows for an understanding of this non-uniform response to dose escalation – some patients benefit while others are harmed. Instead of rejecting the hypothesis that dose-escalation is beneficial, GARD allows us see which patients would benefit most from dose optimization – permitting next generation trials of personalized RT dose.

Today, radiation therapy is prescribed using an empirically derived, one-size-fits-all approach, a paradigm in which patients with a given cancer type receive uniform doses of RT. This pooled analysis demonstrates that GARD, a quantification of the biological effect of RT dose, is predictive of RT treatment benefit. We postulate that a GARD-based framework of RT should be adopted as the new paradigm for trial design and radiation dosing.

References

1. Regaud, C. & Ferroux, R. Discordance des effects de rayons x, d'une part dans la peu, d'autre part dans le testicle, par le fractionment de la dose. *C.R. Soc. Biol.* **97**, 431–34 (1927).
2. Hall, E. J. & Giaccia, A. J. *Radiobiology for the Radiologist*, vol. 6 (Lippincott Williams & Wilkins, 2006).
3. Eschrich, S. A. *et al.* A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. *International Journal of Radiation Oncology* Biology* Physics* **75**, 489–496 (2009).
4. Scott, J. G. *et al.* A genome-based model for adjusting radiotherapy dose (gard): a retrospective, cohort-based study. *The Lancet Oncology* **18**, 202–211 (2017).
5. Abazeed, M. E. *et al.* Integrative radiogenomic profiling of squamous cell lung cancer. *Cancer research* **73**, 6289–6298 (2013).
6. Yard, B. D. *et al.* A genetic basis for the variation in the vulnerability of cancer to dna damage. *Nature communications* **7**, 1–14 (2016).
7. Pitter, K. L. *et al.* Pathogenic atm mutations in cancer and a genetic basis for radiotherapeutic efficacy. *JNCI: Journal of the National Cancer Institute* (2020).
8. Marcar, L. *et al.* Acquired resistance of egfr-mutated lung cancer to tyrosine kinase inhibitor treatment promotes parp inhibitor sensitivity. *Cell reports* **27**, 3422–3432 (2019).
9. Lou, B. *et al.* An image-based deep learning framework for individualising radiotherapy dose: a retrospective analysis of outcome prediction. *The Lancet Digital Health* **1**, e136–e147 (2019).
10. Eschrich, S. *et al.* Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. *International Journal of Radiation Oncology* Biology* Physics* **75**, 497–505 (2009).
11. Ahmed, K. A. *et al.* The radiosensitivity index predicts for overall survival in glioblastoma. *Oncotarget* **6**, 34414–34422 (2015).
12. Ahmed, K. A. *et al.* Differences between colon cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential oligometastatic sbrt patient selection. *Int J Radiat Oncol Biol Phys* (2015). URL http://www.ncbi.nlm.nih.gov/pubmed/25838188. DOI 10.1016/j.ijrobp.2015.01.036.
13. Ahmed, K. *et al.* Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes following sbrt. *Int J Radiat Oncol Biol Phys* In press (2016).
14. Ahmed, K. A. *et al.* Radiosensitivity of lung metastases by primary histology and implications for stereotactic body radiation therapy using the genomically adjusted radiation dose. *J Thorac Oncol* **13**, 1121–1127 (2018). URL https://www.ncbi.nlm.nih.gov/pubmed/29733909. DOI 10.1016/j.jtho.2018.04.027.
15. Eschrich, S. A. *et al.* Validation of a radiosensitivity molecular signature in breast cancer. *Clinical Cancer Research* **18**, 5134–5143 (2012).
16. Torres-Roca, J. F. *et al.* Integration of a radiosensitivity molecular signature into the assessment of local recurrence risk in breast cancer. *International Journal of Radiation Oncology* Biology* Physics* **93**, 631–638 (2015).
17. Strom, T. *et al.* Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. *Radiotherapy and Oncology* **117**, 159–164 (2015).
18. Strom, T. *et al.* Regional radiation therapy impacts outcome for node-positive cutaneous melanoma. *J Natl Compr Canc Netw* **15**, 473–482 (2017). URL https://www.ncbi.nlm.nih.gov/pubmed/28404758.
19. Sjöström, M. *et al.* Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors. *Breast Cancer Research* **20**, 64 (2018).
20. Locati, L. D. *et al.* Mining of self-organizing map gene-expression portraits reveals prognostic stratification of hpv-positive head and neck squamous cell carcinoma. *Cancers* **11**, 1057 (2019).
21. Mohammadi, H. *et al.* Using the radiosensitivity index (rsi) to predict pelvic failure in endometrial cancer treated with adjuvant radiation therapy. *International Journal of Radiation Oncology* Biology* Physics* **106**, 496–502 (2020).
22. Thiruthaneeswaran, N. *et al.* Oc-1031: The radiosensitivity index predicts benefit from hdr brachytherapy in high-risk prostate cancer. *Radiotherapy and Oncology* **152**, S1086–S1087 (2020).

23. Harrell Jr, F. E. *Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis* (Springer, 2015).

24. Ahmed, K. A. *et al.* Utilizing the genomically adjusted radiation dose (gard) to personalize adjuvant radiotherapy in triple negative breast cancer management. *EBioMedicine* **47**, 163–169 (2019).

25. Scott, J. G. *et al.* Personalizing radiotherapy prescription dose using genomic markers of radiosensitivity and normal tissue toxicity in non-small cell lung cancer. *Journal of Thoracic Oncology* (2020).